This website is an international information resource intended for international healthcare professionals with an interest in FORXIGA in T1D. FORXIGA has an approved license in the EU in T1D, and this site is not intended for healthcare professionals outside of the EU or within the UK.

Although the Internet serves a global community, the pharmaceutical industry is subject to country-specific regulatory considerations. This means that the registration status and approved product labels of FORXIGA may not be the same in different countries.
Information on the site is derived from the Summary of Product Characteristics (SmPC) for FORXIGA. Please refer to your local Prescribing Information for full details.

US HEALTHCARE PROFESSIONALS: This website is not intended for US healthcare professionals. If you are a US-based healthcare professional, please click here: https://www.farxiga.com/

PATIENTS: This website is intended for healthcare professionals only. If you are a patient living in the EU, please read the Patient Information Leaflet, which has been written for patients and provides information about taking or using this medicine. Learn more by reading the Summary of Product Characteristics (SmPC). Please contact your healthcare professional or product information in your local country for specific information about this product.

Reporting Adverse Events
AstraZeneca monitors the safety of our products by collecting, evaluating, and reporting adverse events/side effects from a variety of sources. This is a critical component in the development of the prescribing information that provides healthcare professionals with the benefit/risk information they need to make appropriate prescribing decisions. Please use the following link to report an adverse event: https://aereporting.astrazeneca.com